Last €16.39 EUR
Change Today -0.56 / -3.30%
Volume 105.0
AB3A On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:37 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - sarepta therapeutics inc (AB3A)

Name (Connections)Board RelationshipsTitleKey Developments
William Goolsbee 6 RelationshipsChairman, Member of Audit Committee and Member of Compensation Committee 
John Hodgman B.S., M.B.A. 6 RelationshipsDirector, Chairman of Audit Committee and Member of Compensation Committee  
M. Behrens Ph.D. 20 RelationshipsDirector, Chairwoman of Compensation Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee 
Anthony Chase 177 RelationshipsDirector, Member of Audit Committee and Member of Nominating & Corporate Governance Committee 

Compensation Committee* - sarepta therapeutics inc (AB3A)

Name (Connections)Board RelationshipsTitle
M. Behrens Ph.D. 20 RelationshipsDirector, Chairwoman of Compensation Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
William Goolsbee 6 RelationshipsChairman, Member of Audit Committee and Member of Compensation Committee
John Hodgman B.S., M.B.A. 6 RelationshipsDirector, Chairman of Audit Committee and Member of Compensation Committee
Gil Price M.D. 13 RelationshipsDirector, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee
AB3A Compensation vs. Industry
580.0K
371.8K
Chief Executive Officer
427.2K
273.7K
Chief Financial Officer
Share price activity for SAREPTA THERAPEUTICS INC (AB3A)
52 Week Price Performance
AB3A
Industry Average

Nominating Committee* - sarepta therapeutics inc (AB3A)

Name (Connections)Board RelationshipsTitleKey Developments
Gil Price M.D. 13 RelationshipsDirector, Chairman of Nominating & Corporate Governance Committee and Member of Compensation CommitteeSarepta Therapeutics, Inc. Announces Executive Changes
07/31/14
Hans Wigzell M.D., Ph.D. 134 RelationshipsChairman of the Corporate Strategy Board, Director and Member of Nominating & Corporate Governance CommitteeSarepta Therapeutics, Inc. Terminates Arthur Krieg, M.D., as Senior Vice President and Chief Scientific Officer
07/24/14
M. Behrens Ph.D. 20 RelationshipsDirector, Chairwoman of Compensation Committee, Member of Audit Committee and Member of Nominating & Corporate Governance CommitteeSarepta Therapeutics Names Arthur Krieg, M.D., as Senior Vice President and Chief Scientific Officer
01/9/14
Anthony Chase 177 RelationshipsDirector, Member of Audit Committee and Member of Nominating & Corporate Governance CommitteeSarepta Therapeutics, Inc. Announces Executive Changes, Effective October 4, 2013
10/4/13

Corporate Governance Committee* - sarepta therapeutics inc (AB3A)

Name (Connections)Board RelationshipsTitle
M. Behrens Ph.D. 20 RelationshipsDirector, Chairwoman of Compensation Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
Anthony Chase 177 RelationshipsChairman, Member of Audit Committee and Member of Compensation Committee
Gil Price M.D. 13 RelationshipsDirector, Chairman of Audit Committee and Member of Compensation Committee
Hans Wigzell M.D., Ph.D. 134 RelationshipsDirector, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee
AB3A and Competitor
Insiders vs. External
Board
14%
86%
Sarepta Therapeutics, Inc.
7%
93%
Gilead Sciences Inc.
29%
71%
Hemispherx Biopharma, Inc.
8%
92%
Baxter International Inc.
17%
83%
SciClone Pharmaceuticals, Inc.
15%
85%
AstraZeneca PLC
Insiders
External Board Members

Executive Committee* - sarepta therapeutics inc (AB3A)

Name (Connections)Board RelationshipsTitle
Denis Burger Ph.D. 46 RelationshipsFormer Chairman of the Board, Chief Executive Officer and Member of Executive Committee
K. Forrest 13 RelationshipsFormer Director and Member of Compensation Committee
Alan Timmins 7 RelationshipsFormer President and Chief Operating Officer
Dwight Weller Ph.D. 0 RelationshipsFormer Senior Vice President of Chemistry & Manufacturing
Management Effectiveness Relative to the Industry
Return on Equity
70.0x
Return on Assets
NM
Return on Total Capital
NM
TEV/Total Revenue(LTM)
NM

Advisory Committee* - sarepta therapeutics inc (AB3A)

Name (Board Relationships)/Title Board Affiliations
Hans Wigzell 134 Relationships
Chairman of the Corporate Strategy Board, Director and Member of Nominating & Corporate Governance Committee
No other board affiliations
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €16.39 EUR -0.56

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,339 GBp -6.00
Baxter International Inc $74.97 USD +0.28
Gilead Sciences Inc $91.50 USD -0.05
Hemispherx Biopharma Inc $0.28 USD +0.005
SciClone Pharmaceuticals Inc $4.84 USD +0.02
View Industry Companies
 

Industry Analysis

AB3A

Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.0x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.